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Palliative treatmentin oesophagogastric adenocarcinoma, as well as the effect on overall survival (OS).
Methods: Synchronous metastatic oesophagogastric adenocarcinoma patients (2010e2017)
were selected from the Netherlands Cancer Registry. Hospitals were categorised in volumes
quartiles. The association between hospital systemic treatment volume and the use of beyond
first-line treatment was assessed using trend and multivariable logistic regression analyses. OS
was compared between hospitals with high and low beyond first-line treatment administration
and treatment strategies using KaplaneMeier curves with log-rank test and multivariable Cox
proportional hazard regression.
Results: Beyond first-line treatment was administered in 606 of 2,466 patients who received
first-line treatment, and increased from 20% to 31% between 2010 and 2017 (P < 0.001).
The lowest hospital volumes were independently associated with lower beyond first-line treat-
ment administration compared to the highest volume (OR 0.62, 95% CI 0.39e0.99; OR 0.67,
95% CI 0.48e0.95). Median OS was higher in all patients treated in hospitals with a high
versus low beyond first-line treatment administration (7.9 versus 6.2 months, P < 0.001).
Second-line paclitaxel/ramucirumab was administered most frequently and independently
associated with longer OS compared to taxane monotherapy (HR 0.74, 95% CI 0.59e0.92).
Conclusion: Higher hospital volume was associated with increased beyond first-line treatment
administration in oesophagogastric adenocarcinoma. Second-line paclitaxel/ramucirumab re-
sulted in longer survival compared to taxane monotherapy.
ª 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Life expectancy of patients with metastatic oesophago-
gastric cancer is poor [1]. Palliative systemic therapy
aims to prolong survival while maintaining quality of
life [2e5]. Median time from start of first-line systemic
treatment to failure was only 4.6 months in a real-world
patient cohort [6]. Therefore, beyond first-line, i.e. sec-
ond and third-line, treatment options are needed.
Single-agent chemotherapy such as irinotecan [7] or a
taxane [8,9] have demonstrated activity in second line. A
second-line regimen containing the VEGF inhibitor
ramucirumab with or without a taxane has shown to
have an additional survival benefit when administered
for oesophagogastric adenocarcinoma [10,11]. Although
trials on third-line treatment are still scarce, increasing
evidence confirms this could be beneficial in highly
selected patients [12].
Since oesophagogastric cancer has a relatively low
incidence, and only a part of patients who receive
palliative systemic therapy are eligible for beyond first-
line treatment, the experience in its administration of
might be limited within individual centers. Therefore,
the beyond first-line treatment administration could
vary between hospitals. If so, it could be related to the
number of patients treated in a hospital, i.e. hospital
volume, as this has been observed in the administration
of first-line systemic treatment [13] and the probability
of undergoing curative treatment [14,15] of oesophago-
gastric cancer as well.
The effect of hospital volume on the use of beyond
first-line treatment has not been described yet. More-
over, the proportion of patients that receives beyond
first-line treatment, the type of treatment that isadministered, and the outcomes of these patients in
clinical practice are unknown. Nationwide real-world
data on the use and benefit of beyond first-line treatment
in oesophagogastric adenocarcinoma patients could
provide valuable information on outcomes of patients
who have received these treatments. In this population-
based study, we analysed the association between hos-
pital volume and the use of beyond first-line treatment,
and the effects of beyond first-line palliative systemic
treatment strategies on overall survival (OS) and time to
failure of treatment (TTF).
2. Materials and methods
2.1. Data collection
Patients of 18 years with an adenocarcinoma of the
oesophagus, gastro-oesophageal junction, or stomach
((International Classification of Diseases for Oncology
(ICD-O), ICD-O-3: C15 and C16 [16]) with synchronous
metastases who received palliative systemic treatment,
were identified from the Netherlands Cancer Registry
(NCR). The NCR is a population-based registry that
covers the total Dutch population of more than 17
million people and is directly linked to the nationwide
network and registry of histo- and cytopathology in The
Netherlands (PALGA) [17] that comprises all histolog-
ically confirmed cancer diagnoses. Patients were
included if diagnosed during 2015e2017, or in a subset
of Dutch hospitals during 2010e2014. This subset was
selected because of logistic limitations, and regarded as a
representative sample of all Dutch hospitals [6]. Two
hospitals were excluded, because of missing details on
treatment.
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extracted from medical records by specially trained
registrars. Human epidermal growth factor receptor 2
(HER2) data were retrieved from PALGA [18]. Data on
vital status were obtained by annual linkage to the
Dutch Personal Records Database and updated until
February 1, 2020.2.2. Systemic treatment
Assumptions regarding systemic treatment are listed in
Supplementary Table 1. A systemic treatment line was
defined as systemic therapy agents that started
within 3 days of each other and were given until sus-
pension, as described earlier [6]. A sequential treatment
line was specified as treatment in which an agent of a
drug group was administered that was not used in thePatients with metastatic 
oesophagogastric cancer treated 
with first-line systemic therapy
n=2,738
Subset of patients with metastatic 
oesophagogastric adenocarcinoma
(T1-4bNalllM1) treated with first-line 
systemic therapy diagnosed in 
2010-2014 
n=1,217
All patients wit
oesophagogastric a
(T1-4bNalllM1) treat
systemic therapy
2015-2
n=1,5
Patients treated with first-line 
systemic treatment
n=2,466
Patients who died ≤90 days after 
stop of first-line treatment
n=1,133
Patients who did n
after stop of first
n=1,3
Patients treated with beyond-first 
line systemic treatment
n=56 (5%)
Patients treated w
line systemic
n=550 (
Patients treated with beyond-first 
line systemic treatment
n=606
Fig. 1. Patientpreceding line, with the exception of trastuzumab and
ramucirumab.
The proportion of patients that received beyond first-
line treatment was described in all patients, and in those
considered eligible for this treatment, i.e. if they survived
>90 days after stop of first-line treatment. This time
frame was chosen because systemic treatment adminis-
tration in the last months before death is generally
considered undesirable [19,20].
2.3. Hospital volume
Per hospital, the volume of all oesophagogastric
adenocarcinoma patients who received systemic treat-
ment in curative setting, or palliative setting for syn-
chronous metastatic disease was calculated. With the
aim to reflect current practice, the volume of recent
years (2015e2017) was used. Hospitals were categorisedExcluded (n=272):
- Patients with esophageal, gastro-esophageal 
junction or cardia carcinoma and non-regional head 
and neck lymph node metastases only (n=95)
- Patients treated with chemoradiotherapy (n=96)
- Patients that received first- or second-line systemic 
treatment abroad (n=45)
- Patients in whom first- or second-line systemic 
therapy regimens were not specified (n=14)
- Patients without follow-up data on vital status (n=8)
- Patients that participated in a first-line trial and 
possibly received a placebo (n=9)
- Patients that started with first-line systemic therapy 
and in which the primary tumor was then considered
to be other than oesophagogastric (n=5) 
h metastatic 
denocarcinoma
ed with first-line 
 diagnosed in 
017
21
ot die ≤90 days 
-line treatment
33
ith beyond-first 
 treatment
41%)
selection.
Table 1
Patient characteristics before start of second-line systemic treatment
and details of first-line treatment in patients who received second-line
therapy (nZ606).
Characteristics Patients who received
second-line therapy
(n Z 606)
No. (%)
Female 139 (23%)
Age, years, median (IQR) 64 (57, 70)
<60 214 (35%)
60-69 234 (39%)
70-79 146 (24%)
80 12 (2%)
Performance status
0 or 1 300 (49%)
2 42 (7%)
Unknown 264 (44%)
Number of comorbidities
0 381 (63%)
1 155 (26%)
2 51 (8%)
Unknown 19 (3%)
Tumour location
Oesophagus 272 (45%)
Gastro-oesophageal junction or
cardia
134 (22%)
Stomach 200 (33%)
Lauren classification
Intestinal 288 (48%)
Diffuse 123 (20%)
Mixed 19 (3%)
Indeterminate 20 (3%)
Unknown 156 (26%)
HER2 overexpression
Positive 119 (20%)
Negative 355 (59%)
Unknown 3 (0%)
Not tested 129 (21%)
Metastatic sites
1 230 (38%)
2 376 (62%)
Distant lymph node metastases 280 (46%)
Liver metastases 369 (61%)
Peritoneal metastases 188 (31%)
Lung metastases 151 (25%)
Bone metastases 99 (16%)
Other metastatic sites 108 (18%)
First-line treatment characteristics
First-line systemic treatment strategy
Monotherapy 26 (4%)
Doublet chemotherapy 303 (50%)
Triplet chemotherapy 183 (30%)
Trastuzumab-containing regimen 90 (15%)
Non-trastuzumab targeted therapy-
containing regimen
4 (1%)
Duration first-line treatment, months,
median (IQR)
3.7 (2.3, 6.2)
Unknown 7 (1%)
Reasons discontinuation first-line treatment
Progressive disease 568 (94%)
Toxicity 18 (3%)
Patient’s request 0 (0%)
Other 4 (1%)
Unknown 16 (3%)
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proportion of patients that received beyond first-line
treatment. Furthermore, hospitals were divided above
and below the median proportion of patients that
received beyond first-line treatment per hospital, and OS
of all patients was compared between these categories.
2.4. Overall survival and time to failure
OS was assessed from start of a treatment line until
death or end of follow-up. To take into account all
reasons for treatment discontinuation besides progres-
sive disease, we used TTF as a proxy for progression-
free survival (Supplementary Table 1). OS and TTF of
second-line treatment strategies that were applied in at
least 10% of the patients were compared.
2.5. Statistical analysis
Patient and tumour characteristics are displayed with
counts and percentages, or medians and interquartile
ranges (IQRs). Differences between groups were ana-
lysed using chi-squared tests, Fisher’s exact tests or
ManneWhitney U tests, whichever was appropriate.
The association between beyond first-line treatment
administration with hospital volume and over time were
analysed using the Chi-square and Cochran-Armitage
trend test. The association between first-line hospital
volume and the probability of receiving beyond first-line
treatment was tested using multivariable logistic
regression, with adjustment for factors that could be
associated with treatment administration. OS/TTF of
second-line treatment were analysed with
KaplaneMeier curves and log-rank tests. The associa-
tion between hospital volume, second-line treatment
strategies and OS/TTF were tested using multivariable
Cox proportional hazard regression analyses by
adjusting for relevant patient and tumour characteris-
tics. P values < 0.05 were considered statistically sig-
nificant. Analyses were performed using SAS software
(version 9.4, SAS institute, Cary, NC, USA).
3. Results
3.1. Beyond first-line treatment administration
Of all 2,466 patients who received first-line systemic
treatment, second-, third-, fourth- and fifth-line treat-
ment were administered in 25% (n Z 606), 4%
(n Z 107), 1% (n Z 19) and 0.1% (n Z 3), respectively.
Three patients had not finished first-line treatment at
end of follow-up. We observed a gradual increase in the
administration of beyond first-line treatment between
2010 and 2017 (from 20% to 31%; P < 0.001). First-line
mono and triplet chemotherapy administration
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to 6% and 44% to 21%, respectively), while the use of
first-line doublet and trastuzumab therapy increased
(34% to 57%, and 6% to 16%, respectively). Neverthe-
less, still most patients were treated with doublets or
triplets (79% in 2010e2014 and 77% in 2015e2018).
Of the patients who did not die within 90 days and
therefore were considered eligible to receive beyond first-
line treatment, 41% received beyond first-line treatment,
compared to 5% of non-eligible patients (Fig. 1). Over
time, this proportion increased in eligible patients from
31% to 48% between 2010 and 2017 (P < 0.001). Eligible
patients had a better performance status, less comorbid-
ities, less affected and different metastatic sites, more
frequently a oesophageal/GEJ tumour and HER2 over-
expression compared to non-eligible patients
(Supplementary Table 2). Moreover, they received less
often first-line monotherapy, and more often a doublet or
trastuzumab-containing regimen.3.2. Second-line treatment
Median age before start of second-line treatment was 64
years (nZ 606, Table 1). Performance status was 0e1 in
49% of the patients, 2 in 7%, and unknown in 44%.
Half of the patients (n Z 303) received first-line dou-
blets. Patients treated with first-line trastuzumab-con-
taining regimens received most often second-line
treatment (32%), followed by first-line doublet (26%)
and triplet (24%) chemotherapy, non-trastuzumab tar-
geted therapy-containing treatment (15%) and mono-
therapy (11%; P < 0.001; Fig. 2).
Forty-four different second-line regimens were
administered (Fig. 2). Paclitaxel and ramucirumab was
used most frequently (35%), followed by taxane mono-
therapy (20%) and doublet chemotherapy (20%;
Supplementary Table 3). Of the 44 patients who received
trastuzumab-containing treatment, 23 also received first-
line trastuzumab with a different chemotherapy
backbone.Table 2
Probability of receiving beyond first-line systemic treatment per hospital v
(nZ2,466).
Hospital volume Hospitals No. Patients No. Beyond first-li
Q1 - <18 patients 17 233 40 (17%)
Q2 - 18e41 patients 19 451 88 (20%)
Q3 - 42e82 patients 19 749 184 (25%)
Q4 - 83 patients 19 1033 294 (28%)
OR, odds ratio, CI, confidence interval, Q1-Q4, quartiles 1e4.
Hospitals in which patients received first-line systemic treatment were cate
adenocarcinoma patients treated with systemic therapy with either curative
a Cochran-Armitage trend test.
b Odds ratios were adjusted for sex, age, number of comorbidities, primar
within 90 days after stop of systemic treatment.In 2011, 38% of the patients received taxane mono-
therapy, which decreased to 8% in 2017. The adminis-
tration of paclitaxel and ramucirumab increased from
22% in 2015, i.e. the first year that ramucirumab was
available apart from clinical studies in the Netherlands,
to 58% in 2017.3.3. Beyond second-line treatment
Twenty-seven different third-line regimens were admin-
istered (n Z 107), consisting of combination (doublet or
triplet) chemotherapy (30%), non-trastuzumab targeted
therapy-containing regimens (18%), irinotecan (16%)
and non-irinotecan monotherapy (16%), paclitaxel and
ramucirumab (10%) and trastuzumab-containing regi-
mens (10%).
Fourth-line systemic treatment was applied in 19
patients, consisting of irinotecan (n Z 8) and non-
irinotecan monotherapy (n Z 3), trastuzumab-
containing regimens (n Z 3), paclitaxel and ramucir-
umab (n Z 2), combination chemotherapy (n Z 2), and
non-trastuzumab targeted therapy-containing regimens
(n Z 1). Fifth-line treatment was applied in three pa-
tients, of whom one received a trastuzumab-containing
regimen, and two monotherapy.3.4. Hospital volume
Hospital volumes were categorised in <18 (Q1), 18e40
(Q2), 41e82 (Q3) and 83 (Q4) adenocarcinoma pa-
tients treated with systemic therapy in 2015e2017
(Table 2). A positive trend was observed in the pro-
portion of patients who received second-line treatment
over the hospital volume quartiles, which increased from
17% to 28% (P < 0.001). Q1 and Q2 were associated
with a lower probability of beyond first-line treatment
administration compared to Q4 (adjusted odds ratio
[OR] 0.62, 95% confidence interval [CI] 0.39e0.99 and
OR 0.67, 95% CI 0.48e0.95; Table 2).olume quartile in patients who received palliative systemic treatment
ne treatment No. (%) P value Multivariable logistic
regression
ORb 95% CI P value
<0.001a 0.62 0.39e0.99 0.045
0.67 0.48e0.95 0.024
0.99 0.76e1.30 0.945
Ref
gorised in quartiles based on the hospital volume of oesophagogastric
or palliative intent, and who were diagnosed between 2015 and 2017.
y tumour location, Lauren classification, year of diagnosis and death
Fig. 2. First- and second-line systemic treatment strategies in all patients (nZ 2,466) and second-line treatment regimens (nZ 606). First-
line systemic treatment strategies were subdivided in chemotherapy regimens (monotherapy, doublet and triplet), trastuzumab-containing
regimens and non-trastuzumab targeted therapy-containing regimens. Second-line treatment strategies were administered in 606 patients,
and subdivided in chemotherapy regimens (taxane monotherapy, non-taxane monotherapy, doublet and triplet), paclitaxel and ramu-
cirumab, trastuzumab-containing regimens, and non-trastuzumab targeted therapy-containing regimens. The word cloud shows all 44
second-line systemic therapy regimens that were administered. Font size of the word corresponds to the number of patients that received
the regimen.
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tients that received beyond first-line treatment was
0e71%, with a median of 21% (IQR 13%, 32%). When
categorised in either high (21%) or low (<21%) pro-
portions of beyond first-line treatment administration,
median OS of all patients who received first-line treat-
ment in hospitals that treated a high proportion of their
patients with beyond first-line treatment was longer
(7.9 months) compared to hospitals with a low propor-
tion (6.2 months; P < 0.001; Fig. 3).
3.5. Overall survival and time to failure
Overall, median OS since start of second-line treatment
was 5.4 (IQR 2.8, 9.0) and TTF 3.4 (IQR 1.8, 5.6)
months (n Z 606). Median OS since start of third-line
treatment was 5.4 (IQR 3.0, 9.1) months, and TTF 3.1
(IQR 1.8, 6.2) months (n Z 107). Survival of fourth-
and fifth-line treatment was not calculated because of
the limited number of patients.
Median OS of second-line paclitaxel and ramucir-
umab, doublet chemotherapy and taxane monotherapy
was 6.1, 5.5 and 4.1 months, respectively (Fig. 4).
Paclitaxel and ramucirumab resulted in longer OS and
TTF in univariable (P Z 0.008 and P Z 0.002, respec-
tively) and multivariable analyses (adjusted hazard ratio
[HR] 0.71, 95%CI 0.52e0.95) and TTF (HR 0.61, 95%
CI 0.44e0.83) compared to taxane monotherapy (Table
3). Doublets resulted neither in better OS (HR 0.76, 95%
CI 0.57e1.01) nor TTF (HR 0.75, 95% CI 0.56e1.01)Fig. 3. Kaplan Meier curves for overall survival in patients who receiv
and low proportion of beyond first-line treatment administration. Ove
treatment (n Z 2,466), stratified for hospitals with a high and low prop
beyond first-line systemic treatment.than taxane monotherapy. Compared to doublets,
paclitaxel and ramucirumab resulted in similar OS (HR
0.93, 95% CI 0.70e1.24) and TTF (HR 0.81, 95% CI
0.60e1.10).
Lastly, the impact of hospital volume of second-line
treatment on OS was assessed. Adjusted HRs of patients
treated with second-line treatment in lower treatment
volume hospitals (Q1, Q2 and Q3) compared to the
highest volume (Q4) were 1.41, 1.56 and 1.15, respec-
tively, although this was only statistically significant in
Q2 hospitals (Table 4).
4. Discussion
In this nationwide cohort of 2,466 patients with syn-
chronous metastatic oesophagogastric adenocarcinoma
who received first-line palliative systemic treatment, we
observed an association between hospital volume and
the probability of receiving beyond first-line treatment,
and overall survival. In recent years, studies in the
curative setting showed that oesophagogastric cancer
patients treated in high-volume hospitals have a higher
chance of receiving treatment, and better outcomes
[14,15,21e25]. Our study adds to the increasing body of
evidence that this finding also applies in the metastatic
setting [13,18]. Clearly, the simple fact that a patient
received treatment could explain the improved survival
in high-volume centers, as beyond first-line treatment
has been shown to improve survival compared to best
supportive care [9,10]. However, importantly, weed palliative systemic treatment stratified for hospitals with a high
rall survival in all patients who received at least first-line systemic
ortion (above and below the median 21%) of patients treated with
Table 3
Cox regression analyses for OS and TTF of second-line systemic treatment strategies.
Overall survival (n Z 457) Time to failure of second-line treatment (n Z 457)
Patients No. Median
OS (months)
Univariable analyses Multivariable analyses Median TTF
(months)
Univariable analyses Multivariable analyses
HR 95% CI P value HR 95% CI P value HR 95% CI P value HR 95% CI P value
Second-line systemic treatment strategy
Taxane monotherapy 122 4.1 Ref Ref 2.5 Ref Ref
Doublet chemotherapy 120 5.5 0.86 0.67 1.11 0.246 0.76 0.57 1.01 0.057 3.9 0.83 0.64 1.09 0.185 0.75 0.56 1.01 0.056
Paclitaxel þ ramucirumab 215 6.1 0.73 0.59 0.92 0.007 0.71 0.52 0.95 0.021 4.1 0.69 0.55 0.88 0.002 0.61 0.44 0.83 0.002
Sex
Male 350 5.5 Ref Ref 3.6 Ref Ref
Female 107 5.0 0.90 0.72 1.12 0.346 0.89 0.70 1.14 0.358 3.4 0.99 0.79 1.25 0.925 1.01 0.78 1.30 0.953
Age e e 0.99 0.98 1.00 0.149 1.00 0.99 1.01 0.443 e 0.99 0.98 1.00 0.073 0.99 0.98 1.00 0.145
Performance status
0 or 1 224 5.9 Ref Ref 3.6 Ref Ref
2 35 4.7 0.98 0.68 1.42 0.908 0.99 0.68 1.44 0.936 2.7 0.84 0.58 1.23 0.377 0.82 0.55 1.21 0.315
Unknown 198 4.9 1.21 1.00 1.47 0.057 1.11 0.91 1.37 0.304 3.5 1.06 0.86 1.30 0.587 0.96 0.78 1.18 0.689
Number of comorbidities
0 296 5,3 Ref Ref 3.4 Ref Ref
1 113 5,1 1.07 0.85 1.33 0.576 1.07 0.85 1.36 0.568 3.4 1.01 0.80 1.26 0.954 1.07 0.84 1.36 0.602
2 36 6.9 0.78 0.55 1.11 0.171 0.72 0.50 1.05 0.086 5.1 0.64 0.43 0.95 0.028 0.62 0.41 0.93 0.022
Unknown 12 5.6 0.98 0.55 1.75 0.984 1.04 0.57 1.88 0.909 4.7 0.90 0.48 1.70 0.753 1.09 0.57 2.09 0.796
Tumour location
sophagus 185 5.5 Ref Ref 3.5 Ref Ref
Gastro-oesophageal junction or cardia 110 5.7 0.91 0.71 1.16 0.436 1.01 0.78 1.31 0.935 4.2 0.86 0.67 1.11 0.251 0.95 0.73 1.24 0.728
Stomach 162 5.0 1.10 0.89 1.36 0.399 1.13 0.85 1.50 0.405 3.4 1.06 0.85 1.33 0.603 1.11 0.83 1.47 0.486
Lauren classification
Intestinal 211 5.6 Ref Ref 3.4 Ref Ref
Diffuse 104 4.6 1.35 1.06 1.72 0.014 1.21 0.92 1.58 0.177 3.1 1.16 0.90 1.48 0.248 1.01 0.76 1.34 0.950
Mixed 11 4.7 1.03 0.56 1.89 0.923 0.78 0.41 1.48 0.443 4.7 0.80 0.39 1.62 0.533 0.65 0.31 1.36 0.253
Indeterminate 15 4.8 1.81 1.07 3.08 0.028 1.75 1.02 3.01 0.042 2.7 1.52 0.86 2.67 0.150 1.40 0.79 2.49 0.250
Unknown 116 6.1 1.12 0.89 1.41 0.335 1.25 0.98 1.60 0.077 4.7 0.87 0.69 1.11 0.267 0.93 0.72 1.20 0.565
Distant lymph node metastasis 213 5.1 1.16 0.96 1.40 0.121 1.28 1.04 1.58 0.023 3.3 1.25 1.03 1.52 0.025 1.41 1.14 1.75 0.002
Liver metastasis 270 5.5 0.96 0.79 1.16 0.673 1.28 1.01 1.61 0.041 3.4 1.05 0.86 1.28 0.646 1.41 1.10 1.81 0.008
Peritoneal metastasis 160 4.8 1.25 1.03 1.53 0.024 1.33 1.03 1.71 0.027 3.1 1.24 1.02 1.52 0.035 1.41 1.09 1.83 0.009
Lung metastasis 115 5.1 1.25 1.01 1.56 0.040 1.28 1.02 1.61 0.037 3.5 1.19 0.95 1.48 0.134 1.12 0.88 1.42 0.368
Bone metastasis 68 3.6 1.70 1.30 2.21 <0.001 1.86 1.39 2.50 <0.001 2.5 1.63 1.25 2.13 <0.001 1.81 1.35 2.43 <0.001
Other metastases locations 90 4.8 1.20 0.91 1.51 0.126 1.07 0.82 1.38 0.622 3.4 1.20 0.94 1.53 0.140 1.15 0.88 1.50 0.316
Year of diagnosis - - 0.96 0.92 1.00 0.071 0.98 0.93 1.04 0.592 - 0.95 0.91 0.99 0.027 1.00 0.94 1.06 0.983
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Table 4
Cox regression analyses for the association between hospital volume
and overall survival in patients who received beyond first-line treat-
ment (nZ606).
Hospital volume Patients (n Z 606)
No. (%)
HRa 95% CI P value
Q1 - <18 patients 34 (6%) 1.41 0.92e2.17 0.111
Q2 - 18e41 patients 82 (14%) 1.56 1.15e2.13 0.005
Q3 - 42e82 patients 188 (31%) 1.16 0.93e1.44 0.193
Q4 - 83 patients 302 (50%) Ref
HR, hazard ratio, CI, confidence interval, Q1-Q4, quartiles 1e4.
Hospitals in which patients received second-line systemic treatment
were categorised in quartiles based on the hospital volume of oeso-
phagogastric adenocarcinoma patients treated with (neo)adjuvant
systemic therapy and synchronous metastatic oesophagogastric cancer
patients treated with palliative systemic therapy between 2015 and
2017.
a Hazard ratios were adjusted for sex, age, performance status,
number of comorbidities, primary tumour location, Lauren classifi-
cation, metastatic sites, and year of diagnosis.
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palliative systemic treatment (with or without beyond
first-line treatment) in a hospital with a high use of
beyond first-line treatment was longer compared to
hospitals with a low use of beyond first-line treatment.
In addition, we showed in multivariable analysis that
HRs for death decreased when the hospital treatment
volume increased, which suggests that not only patient,
tumour and treatment characteristics are related to
better patient outcomes, but also factors which may be
specific to high-volume centers, such as well-developedFig. 4. Kaplan-Meier curves displaying overall survival in patients wh
patients receiving second-line systemic treatment. Second-line systemic
patients are displayed.structures and adequate resources for a multidisci-
plinary treatment approach [13,26].
The heterogeneity of 44 different second-line regi-
mens is in line with the variety of 46 first-line regimens
that we observed earlier [6]. The former Dutch gastric
cancer guideline that was used until 2016 [27] and the
current oesophageal cancer guideline [28] do not specify
recommendations on systemic treatment regimens. This
probably contributed to this heterogeneity, and to the
limited number of patients who received beyond first-
line treatment at all. The publication of the results of
the landmark RAINBOW trial in 2014 [11] and the
subsequent recommendation of its administration in the
national gastric cancer guideline in 2016 [29] probably
boosted the observed increase in the administration of
paclitaxel and ramucirumab in 2017, and the overall rise
in the use of beyond first-line treatment from 31% in
2010 to 48% of the eligible patients in 2017, i.e. the
patients who survived >90 days after stop of first-line
treatment, and will hopefully result in further uptake
of beyond first-line treatment recommendations of
(inter)national guidelines. The rise of beyond first-line
treatment use could also be a result of a better perfor-
mance status in patients after first-line treatment as a
result of increased efficacy, e.g. due to the rise in the
administration of trastuzumab-containing regimens and
decrease in monotherapy use [18], or less toxicity in first
line, e.g. due to the increase in doublet and decrease in
triplet chemotherapy administration [6]. Overall,
beyond first-line treatment was administered in 41% of
eligible patients, which is similar to a recent real-worldo received second-line systemic treatment. Overall survival in 457
treatment strategies that were administered in at least 10% of the
W.P.M. Dijksterhuis et al. / European Journal of Cancer 139 (2020) 107e118116study [30], and in 5% of non-eligible patients. These
results suggest that patient selection for this treatment
and assessment of life expectancy is performed
adequately in most cases [19,20].
The paclitaxel and ramucirumab regimen was admin-
istered in 58% of the patients who received second-line
treatment in 2017, and independently associated with a
longer OS and TTF compared to taxane monotherapy,
which confirms the result of the RAINBOW trial [11].
Although themedianOS in both groups was lower than in
this trial, the median OS difference of 2.2 months was
comparable to our study (RAINBOW: 9.6 versus
7.4 months; our study: 6.1 versus 4.1 months), as well as
the hazard ratios (RAINBOW: HR 0.80, 95%CI
0.68e0.96; our study: HR 0.71, 95% CI 0.52e0.95). Infe-
rior survival rates in population-based studies compared
to trials have been identified frequently [31]. Although we
could not analyze treatment-related toxicity because of
missing data, paclitaxel and ramucirumab have been
consideredwell-tolerated inboth theRAINBOWtrial and
real world [11,32]. Because the introduction of ramucir-
umab changed the landscape of second-line treatment
from 2015 onwards, we adjusted for year of diagnosis in
theCox regression analyses.Whenwe restrict our analyses
to patients diagnosed in 2015e2017, the survival benefit of
paclitaxel and ramucirumab compared to taxane mono-
therapy is even larger (OS: HR 0.61, 95% CI 0.42e0.88;
TTF: HR 0.53, 95% CI 0.36e0.79).
There was no survival benefit of doublet chemo-
therapy over taxane monotherapy, which supports the
findings of an earlier meta-analysis [8], while doublet
chemotherapy probably induces more toxicity [6,8].
Other population-based studies on beyond first-line
treatment in oesophagogastric cancer did not compare
outcomes or toxicity between these two strategies
[30,33]. More real-world data on the actual benefit and
harms of second-line doublet chemotherapy are needed
to justify its administration.
Beyond second-line treatment was used in only a few
patients, probably because evidence of its efficacy was
scarce until 2017, and still is. Recent results showing
that trifluridine/tipiracil and nivolumab are third-line
treatment options [34,35] will probably result in
increased third-line treatment administration in the
coming years.
A limitation of this study is that we missed data on
performance status in a considerable number of patients.
We therefore not only adjusted for performance status, but
also for the number of comorbidities, age, and deathwithin
90 days after stop of systemic treatment, as a proxy for
performance status, in order to achieve the most optimal
adjustment for confounders that could be associated with a
patient’s condition and subsequently, beyond first-line
treatment administration. Unfortunately, toxicity data
were unknown no in 76% of the patients. Furthermore, the
heterogeneity in second-line regimens and the subsequent
small group size per regimen resulted in lack of statisticalpower to compare regimens. Moreover, although we
included a nationwide oesophagogastric cancer popula-
tion, our data are restricted to The Netherlands, and
therefore comparable studies in other countries are needed
to confirm our results in different populations. Lastly,
consensus about thedefinitionof systemic treatment lines in
real-world data is currently lacking, although some sug-
gestions have been made [36]. This hindered us from opti-
mally comparing this with other population-based studies
[30,33]. An international agreement on the definition of
treatment lines and the best approach to analyze these data
should be considered in order to enable fair comparisons
between outcomes of population-based studies.
Improving patient selection for beyond first-line
immunotherapy using molecular tumour analysis could
further improve patient outcomes. Results of studies
comparing treatment with the checkpoint inhibitor
pembrolizumab with chemotherapy in patients who have
a tumour with high levels of microsatellite instability and
PD-L1 expression are promising [37,38]. In first-line
treatment, we observed that still not all patients are
tested for the only target that is currently available, i.e.
HER2 [18]. In the light of upcoming targeted therapies,
uptake for biomarker testing must be improved in order
to enhance personalised treatment. The rise of beyond
first-line targeted treatment options should ideally result
in increased administration of it in clinical practice and
improved outcomes in oesophagogastric cancer patients.
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